Dr. Jonathan C. Roberts, M.D.
Pediatrics (Pediatrics Physician)
- Medicare participating
At a glance
- Medical school
- Southern Illinois University School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 229
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Southern Illinois University School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
IL license 125.054688 · WI license 55876 -
Pediatric Emergency Medicine (Pediatrics) Physician
WI license 55876
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Saint Francis Medical Center Peoria, IL
- Carle Health Methodist Hospital Peoria, IL
- St Mary Medical Center Galesburg, IL
- Carle Health Proctor Hospital Peoria, IL
Medical groups
- The Bleeding and Clotting Disorders Institute (10 clinicians)
- Michael D. Tarantino, M.d. S.c. (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 229
- Services billed
- 864
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 170 | 145 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 158 | 44 |
| Anticoagulant management of patient taking warfarin | 59 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 39 | 39 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Warfarin Sodium Other prescribers in Peoria, IL | 184 |
| Eliquis (apixaban) Other prescribers in Peoria, IL | 140 |
| Xarelto (rivaroxaban) Other prescribers in Peoria, IL | 43 |
| Enoxaparin Sodium Other prescribers in Peoria, IL | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 43 payments worth $107,287 in total to this clinician.
| Genzyme Corporation | $37,232 |
|---|---|
| Novo Nordisk Inc | $25,038 |
| Swedish Orphan Biovitrum Ab | $18,727 |
| Sanofi US Services Inc. | $14,912 |
| Takeda Pharmaceuticals U.S.A., Inc. | $11,242 |
| Genentech USA, Inc. | $136 |
| Compensation for services other than consulting (speaking, faculty) | $70,925 |
|---|---|
| Consulting Fee | $22,316 |
| Travel and Lodging | $12,792 |
| Food and Beverage | $1,255 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi US Services Inc. Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $14,912 |
| Swedish Orphan Biovitrum Ab Nov 17, 2025 | Consulting Fee ALTUVIIIO · Hematology | $9,334 |
| Swedish Orphan Biovitrum Ab Oct 27, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to London, Great Britain (UK) | $8,894 |
| Genzyme Corporation May 12, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $8,238 |
| Genzyme Corporation Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $6,920 |
| Genzyme Corporation May 19, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $6,920 |
| Novo Nordisk Inc Jun 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,919 |
| Novo Nordisk Inc Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) Alhemo · Hemophilia | $6,581 |
| Novo Nordisk Inc Sep 30, 2025 | Consulting Fee | $4,050 |
| Novo Nordisk Inc May 1, 2025 | Consulting Fee | $3,713 |
All 34 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) VONVENDI · HEMATOLOGY | $2,008 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) VONVENDI · HEMATOLOGY | $2,008 |
| Swedish Orphan Biovitrum Ab Nov 20, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to London, Great Britain (UK) | $152 |
| Swedish Orphan Biovitrum Ab Nov 17, 2025 | Consulting Fee ALTUVIIIO · Hematology | $9,334 |
| Swedish Orphan Biovitrum Ab Oct 27, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to London, Great Britain (UK) | $8,894 |
| Swedish Orphan Biovitrum Ab Oct 27, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to London, Great Britain (UK) | $347 |
| Novo Nordisk Inc Sep 30, 2025 | Consulting Fee | $4,050 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 11, 2025 | Consulting Fee ADVATE · HEMATOLOGY | $2,008 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 11, 2025 | Consulting Fee | $2,008 |
| Takeda Pharmaceuticals U.S.A., Inc. Sep 11, 2025 | Consulting Fee ADVATE · HEMATOLOGY | $1,205 |
| Novo Nordisk Inc Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) Alhemo · Hemophilia | $6,581 |
| Novo Nordisk Inc Aug 22, 2025 | Travel and Lodging Alhemo · Hemophilia · travel to Aurora, CO · in-kind | $469 |
| Novo Nordisk Inc Aug 22, 2025 | Travel and Lodging Alhemo · Hemophilia · travel to Aurora, CO · in-kind | $20.16 |
| Novo Nordisk Inc Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) Alhemo · Hemophilia | $1,688 |
| Genzyme Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $2,307 |
| Genzyme Corporation Jun 29, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $2,307 |
| Sanofi US Services Inc. Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $14,912 |
| Novo Nordisk Inc Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $861 |
| Novo Nordisk Inc Jun 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,919 |
| Novo Nordisk Inc Jun 7, 2025 | Travel and Lodging travel to Wisconsin Dells, WI · in-kind | $348 |
| Genzyme Corporation May 19, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $6,920 |
| Genzyme Corporation May 19, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Clayton, MO | $240 |
| Genzyme Corporation May 19, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Clayton, MO · in-kind | $229 |
| Genzyme Corporation May 19, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Clayton, MO | $15.25 |
| Genzyme Corporation May 12, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $8,238 |
| Genzyme Corporation May 12, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Tucson, AZ | $1,263 |
| Genzyme Corporation May 12, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Tucson, AZ | $583 |
| Novo Nordisk Inc May 1, 2025 | Consulting Fee | $3,713 |
| Genzyme Corporation Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $6,920 |
| Genzyme Corporation Apr 23, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Chicago, IL | $231 |
| Genzyme Corporation Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $2,636 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) VONVENDI · HEMATOLOGY | $2,008 |
| Genzyme Corporation Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $2,307 |
| Genzyme Corporation Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) ALPROLIX · Hematology | $2,307 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $416,626 in research payments for these studies, mostly to the institutions running them.
- Emicizumab for severe von Willebrand Disease VWD
Genentech, Inc. - Goal Attainment and Physical Activity in People With Hemophilia A
Sanofi US Services Inc. · Terminated · NCT06530030 - TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD)
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
Sanofi US Services Inc. · Active, not recruiting · NCT05911763 - A phase 3, prospective, multicenter, uncontrolled, open-label clinical study to determine the efficacy, safety, and tolerability of rvwf with or without advate in the treatment and control of bleeding episodes, the ef…
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.